Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Recurrence 2Neoplasm Metastasis 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Introns × Gastrointestinal × Clear all
NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
15 enrolled 9 charts
Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

NCT00234182 2005-12-01

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC

The University of Hong Kong

Phase 1/2 Completed
84 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡